MedPath

Effect of Albendazole in combination with Ivermectin in treatment of soil transmitted heminthiasis

Not Applicable
Conditions
Health Condition 1: K639- Disease of intestine, unspecified
Registration Number
CTRI/2022/01/039738
Lead Sponsor
MANKIND PHARMA LTD
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Children in the age group of 6-15 years attending the schools

selected for the study.

2. Parents willing to provide written informed consent to

participate in the trial and assent from children aged 7 and

above.

Exclusion Criteria

1. Presence of any major severe systemic illness, chronic severe

anaemia

2. History of epileptic disorders, visual disturbances, chronic

headache

3. Current use of anti-epileptics

4. Any subject febrile on the day of enrolment

5. Presence of any acute illness, vomiting, headache etc. on the

day of enrolment

6. Recent use of anti-helmintic drugs through governmentâ??s mass

drug administration program within the past 3 months in both

the study subject and any household contacts

7. Known allergy to the study medications

8. Current use of drugs known to have pharmacological interaction with Albendazole or Ivermectin

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath